Your PBM's Network May Be Adequate. But Is It Working?

Key Takeaway: A broad pharmacy network ensures access, but it does not guarantee that a plan is paying the best available rate. Employers and health plans should ask whether retail and specialty claims are evaluated prescription by prescription, rather than relying on aggregate network performance.

I hear it in almost every early conversation with a prospective client. A large employer group. A smart benefits team. A broker who's done the work. And when the conversation turns to pharmacy network strategy, the first question is almost always some version of the same thing:

"How many pharmacies are in the network?" It's a fair question. Members need access to retail, mail, and specialty medications across geographies and care needs. Adequacy matters.

But once adequacy is established, the more important question is usually left unasked: what's the network actually doing for the plan?

Access tells you whether a member can fill a prescription. It doesn't tell you whether the claim is being routed to the best available contract, or whether the plan is paying more than it needs to on a specific drug. Network adequacy is the floor. What happens above it is where the real value is won or lost.

What a Large Pharmacy Network Can Hide

In many PBM models, claims run through a primary network contract at a negotiated rate. Performance is reported in the aggregate: overall discount, overall effective rate, overall savings. On paper, the numbers look consistent.

But pharmacy claims don't behave in the aggregate. They happen one drug, one pharmacy, one member at a time.

Some drug categories perform very well under a given contract. Others are weaker. When everything is averaged together, the strong categories mask the underperformance elsewhere. The plan sees a blended number that looks acceptable. Individual claims are still leaving money on the table.

A large network proves access. It doesn't prove optimization.

Why Pharmacy Network Conversations Always Pivot to Specialty

When network performance comes up, the conversation almost always moves to specialty pharmacy first. Understandably so. A single specialty drug can carry an annual cost in the tens of thousands of dollars. The numbers are visible and the stakes are easy to point to.

But most of a plan's claims volume isn't specialty. It's retail. Hundreds of prescriptions a month, individually unremarkable, collectively enormous. Because the dollar amounts per claim are smaller, the question of whether each one is being optimized rarely gets asked with the same urgency.

It should. At scale, the difference between a retail network that applies one flat rate to every claim and one that evaluates each prescription individually compounds quietly into a number that matters. It just doesn't show up in a single dramatic line item the way a specialty drug does.

Both deserve the same discipline. Most plans only apply it to one.

How PBM Pharmacy Network Ownership Shapes Routing

When a PBM owns a pharmacy, or holds a preferred financial relationship with one, the routing strategy is decided before the first claim arrives. Volume flows toward that channel because the economics point that way. The claims follow the structure the PBM built, not necessarily the best available price.

Nowhere does this matter more than in specialty pharmacy. We contract with more than 100 specialty pharmacy partners and evaluate pricing by drug category, not by relationship. Oncology claims go where oncology pricing is strongest. Immunology and rheumatology follow the same logic. No single pharmacy has the best price on every drug, and a strategy that assumes otherwise costs the plan money it never sees leaving.

For members, none of this surfaces. Their cost never changes as a result of how the prescription is routed. The medication arrives the same way, from their perspective, regardless of which pharmacy fulfilled it.

What changes is what the plan pays.

How Real-Time Retail Pharmacy Claim Evaluation Works

The same logic that drives specialty routing applies to every retail claim. The question is the same: is this prescription being evaluated against the best available rate, or just the most convenient one?

Most PBMs apply one contracted rate across all retail claims and review performance later. By then, the claim has already been paid. The opportunity has already passed.

We maintain multiple retail contracts simultaneously and evaluate all of them at the point of sale, on every prescription, before it processes. One contract might deliver stronger pricing on brands. Another might be more aggressive on generics. A health plan that has negotiated its own pharmacy relationships can layer those contracts into our evaluation as well. The best available rate wins, every time.

For health plans and large employers operating in a disaggregated model, this matters in a specific way. Existing pharmacy relationships don't have to be set aside. They can be layered into the evaluation alongside additional contracts, competing on every prescription by drug category. Where one contract is stronger on brands, it wins. Where another is stronger on generics, it does. The performance follows the pricing, not the relationship

The impact shows up most clearly in generic pricing. When contracts are evaluated prescription by prescription rather than averaged across the book, generic MAC performance runs above 90 percent. That's not a number that comes from one strong contract. It's what happens when every claim finds its best available rate before it settles.

The Network Conversation Worth Having

Network adequacy matters, and PharmPix contracts with 65,000+ retail pharmacies and more than 100 specialty partners nationwide. Any serious PBM conversation should start there.

But the plans that get the most out of their pharmacy benefit don't stop at access. They push further. They ask whether retail claims are being evaluated prescription by prescription or averaged across a flat rate. They ask whether specialty routing reflects net cost or the financial structure of the PBM. They ask whether performance is being measured before claims are paid or only after the fact in a quarterly report.

Those questions are harder to ask. But the plans that ask them consistently find that there's more value in their pharmacy benefit than they realized, not by changing their population or their formulary, but by changing how every claim is evaluated before it settles.

A network can be broad and still underperform. It can be adequate and still leave meaningful savings behind. The plans that understand this aren't just buying access. They're managing what happens inside every claim, on every drug, for every member.

That's where the real network strategy lives. And it's exactly how we think about it at PharmPix.

FAQs

What is the difference between pharmacy network adequacy and pharmacy network performance?

Network adequacy measures whether members can access pharmacies. Network performance measures whether each claim is being routed and priced in a way that delivers the best available value for the plan.

How can employers evaluate retail pharmacy network performance?

Employers should ask whether claims are evaluated prescription by prescription across available contracts or whether performance is measured only through aggregate discounts and retrospective reports.

Why does PBM pharmacy ownership matter for network strategy?

When a PBM owns or has a financial relationship with a pharmacy, claims may be steered toward that channel. Plans should ask whether routing reflects the best available net cost or the PBM’s financial structure.